共 399 条
[1]
Amado RG(2008)Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 1626-1634
[2]
Wolf M(2010)A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer Clin Colorectal Cancer 9 102-107
[3]
Peeters M(2011)Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Ann Oncol 22 1535-1546
[4]
Van Cutsem E(2009)Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 663-671
[5]
Siena S(2015)FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer Eur J Cancer 51 1243-1252
[6]
Freeman DJ(2013)FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study Ann Oncol 24 1769-1777
[7]
Juan T(2005)Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry J Clin Oncol 23 1803-1810
[8]
Sikorski R(2010)Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study Oncology 79 415-422
[9]
Suggs S(2008)KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Ann Oncol 19 508-515
[10]
Radinsky R(2007)Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy Br J Cancer 96 1166-1169